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The authors present the results of treatment of acute type B dissection with endograft and the effect of distal re-entry tear. Their data show that patients with no distal entry tear have better outcome than patients with distal entry tear over the long term. The authors have demonstrated that in patients with only proximal entry tear, the false lumen can be sealed using proximal endograft, and this leads to false lumen thrombosis and remodeling of the aorta. Patients with a false lumen that is perfused by a distal tear will have at best only partial thrombosis of the false lumen; they are more likely to have progression and evolution of the dissection and degeneration of the aorta into a dissecting aneurysm over time, and they are less likely to have aortic remodeling.
The authors chose at the initial setting to cover only the proximal entry tear even in the setting of no visceral artery involvement. In the acute setting, the intima has not yet gotten tough and immobile. It is elastic and can move, and the dissection can evolve. Endovascular therapy in the acute setting can be more effective by expanding the true lumen. It is prudent to cover the distal entry tear, when possible, at the initial setting to prevent further dissection as well as to allow optimal remodeling in the setting of no visceral arterial involvement. The argument against this is that by covering a long segment of thoracic aorta in one setting, the risk of spinal ischemia is increased. The rate of spinal ischemia is 1% to 3% after thoracic endovascular aortic repair. 1 In most instances, these patients experience transient symptoms that resolve with spinal protective measures. On the other hand, the intimal tear becomes tougher and immobile if it is not treated in the acute setting (<2 weeks), and the true lumen may not reexpand optimally at a later time if a stent graft is deployed in the dissected aorta. This could prevent remodeling of the aorta at a second-stage procedure.
Also, it exposes the patient to the risks and cost of a procedure. Further studies are necessary to assess the risk of covering both tears when feasible in one setting. The authors offered endovascular therapy to all patients presenting with acute type B dissection. Early trials seemed to indicate that medical therapy is as good as endovascular therapy. The initial recommendation by the authors of the Investigation of Stent Grafts in Aortic Dissection (INSTEAD) trial in 2009 was that uncomplicated type B dissections should be treated medically with blood pressure control and careful observation because there was no significant improvement in mortality or freedom from complications. 2 These results are still believed to be the standard of care by some of our colleagues. In 2013, the same authors published their 5-year results, which demonstrated that the patients who were treated with endovascular therapy did better in terms of mortality and freedom from adverse events. 3 In fact, some series have shown mortality as high as 50% at 5 years with medical therapy alone. 4, 5 The question is then whether all patients with uncomplicated acute type B dissection should undergo endovascular therapy. In the study by Evangelista et al, they demonstrated that an entry tear >1 cm portends a worse outcome in terms of cumulative survival. 6 Another study by Ray et al showed that aortic diameter >44 mm or false lumen diameter >22 mm is associated with decreased survival. 7 These findings seem to point to selective treatment of acute uncomplicated type B dissection with endovascular therapy. Last, many of us are awaiting the final results of the Study of Thoracic Aortic Type B Dissection Using Endoluminal Repair (STABLE) trial that is testing the composite proximal covered aortic stent graft along with the distal uncovered aortic stent. 8 If the results of this study are favorable, it has the potential to change the paradigm for repair of the dissected aorta in the visceral region.
